Clinical Trials · NCT00577863

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

Name: Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 200
Start date: Jan 2008
Locations: 18 sites, United States
Primary endpoint: Summary of Forteo B Pen Complaints at 8 Weeks

View Teriparatide compound reference